Introduction Dengue continues to emerge as a major global public health challenge, driven by rapid urbanisation, climate change, and the expansion of mosquito habitats. Conventional vector-control strategies such as insecticides, source reduction, and repellents have shown limited and often unsustained impact, while vaccine options remain suboptimal across all serotypes.
Introduction
Dengue continues to emerge as a major global public health challenge, driven by rapid urbanisation, climate change, and the expansion of mosquito habitats. Conventional vector-control strategies such as insecticides, source reduction, and repellents have shown limited and often unsustained impact, while vaccine options remain suboptimal across all serotypes. This has led to growing interest in biologically innovative approaches. One such strategy involves infecting male Aedes aegypti mosquitoes with Wolbachia bacteria, which induces cytoplasmic incompatibility and prevents viable offspring when these males mate with wild-type females, thereby suppressing mosquito populations and potentially reducing dengue transmission.
Problem Statement
Despite multiple preventive strategies, dengue incidence continues to rise globally, highlighting a critical gap in effective, scalable, and sustainable vector-control interventions. While Wolbachia-based methods have shown promise in observational and limited trials, robust randomised evidence demonstrating real-world epidemiologic benefit—particularly using male-only sterile mosquito release (IIT-SIT approach)—has been lacking.
Summary
This large cluster-randomised trial in Singapore demonstrated that releasing Wolbachia-infected male mosquitoes significantly reduced both mosquito density and dengue incidence. Female mosquito abundance dropped markedly in intervention areas, and dengue positivity rates decreased from 21% in control clusters to 6% in intervention clusters. The intervention achieved a protective efficacy of approximately 71–72% after sustained exposure.
These findings provide strong real-world evidence that Wolbachia-based vector suppression is an effective, environmentally sustainable strategy for dengue control. This approach represents a major shift from chemical-based control toward biological population suppression, with potential scalability in urban settings worldwide.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.